We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Read MoreHide Full Article
Corcept Therapeutics Incorporated (CORT - Free Report) announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis (ALS), a degenerative neurologic disorder.
The double-blind, placebo-controlled DAZALS study evaluated two doses of dazucorilant (150 mg and 300 mg) for treating patients with ALS.
The study did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients treated with dazucorilant versus those treated with placebo.
Shares of Corcept were down in pre-market trading on Dec. 12 following the announcement of the news on Dec. 11.
Year to date, shares of Corcept have rallied 85% against the industry’s decline of 4.6%.
Image Source: Zacks Investment Research
More on CORT's DAZALS Study
Data from the study showed that patients who were treated with dazucorilant experienced substantially more gastrointestinal upset compared to those who received placebo at the onset of treatment.
Upon completing the study, patients were eligible to enter an open-label, long-term extension study that evaluated 300 mg of dazucorilant in the given patient population.
The open-label, long-term extension will continue and the overall survival will be assessed in March next year.
Corcept plans to present full data from the DAZALS study at an upcoming medical conference in 2025.
The FDA has granted a Fast Track Designation to dazucorilant for treating ALS.
CORT's Recent Pipeline Progress
Corcept’s lead pipeline candidate, relacorilant, is being evaluated in phase III of the GRACE study to treat Cushing’s syndrome.
Relacorilant is also being investigated in the phase III GRADIENT study for treating patients whose Cushing’s syndrome is caused by adrenal adenoma. While data from the GRACE study will form the basis of the new drug application (NDA) for relacorilant, data from the GRADIENT study will likely support the NDA.
An NDA for relacorilant in Cushing’s syndrome is likely to be submitted shortly.
Corcept is also studying relacorilant in combination with other drugs for treating different cancer indications.
The phase III ROSELLA study is evaluating relacorilant in combination with nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer, with data from the same expected by 2024 end. Another study is evaluating relacorilant in combination with pembrolizumab for treating patients with adrenal cancer along with cortisol excess.
In the past 60 days, estimates for Immunocore’s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time. Year to date, shares of IMCR have declined 55%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 25.57%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Loss per share estimates for 2025 have narrowed from $1.54 to 79 cents during the same time. Year to date, shares of SPRO have declined 21.7%.
SPRO’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 94.42%.
In the past 60 days, estimates for Castle Biosciences’ 2024 bottom line have moved from a loss of 58 cents per share to earnings of 34 cents per share. Loss per share estimates for 2025 have narrowed from $2.13 to $1.84 during the same time. Year to date, shares of CSTL have surged 36.6%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Corcept Therapeutics Incorporated (CORT - Free Report) announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis (ALS), a degenerative neurologic disorder.
The double-blind, placebo-controlled DAZALS study evaluated two doses of dazucorilant (150 mg and 300 mg) for treating patients with ALS.
The study did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients treated with dazucorilant versus those treated with placebo.
Shares of Corcept were down in pre-market trading on Dec. 12 following the announcement of the news on Dec. 11.
Year to date, shares of Corcept have rallied 85% against the industry’s decline of 4.6%.
Image Source: Zacks Investment Research
More on CORT's DAZALS Study
Data from the study showed that patients who were treated with dazucorilant experienced substantially more gastrointestinal upset compared to those who received placebo at the onset of treatment.
Upon completing the study, patients were eligible to enter an open-label, long-term extension study that evaluated 300 mg of dazucorilant in the given patient population.
The open-label, long-term extension will continue and the overall survival will be assessed in March next year.
Corcept plans to present full data from the DAZALS study at an upcoming medical conference in 2025.
The FDA has granted a Fast Track Designation to dazucorilant for treating ALS.
CORT's Recent Pipeline Progress
Corcept’s lead pipeline candidate, relacorilant, is being evaluated in phase III of the GRACE study to treat Cushing’s syndrome.
Relacorilant is also being investigated in the phase III GRADIENT study for treating patients whose Cushing’s syndrome is caused by adrenal adenoma. While data from the GRACE study will form the basis of the new drug application (NDA) for relacorilant, data from the GRADIENT study will likely support the NDA.
An NDA for relacorilant in Cushing’s syndrome is likely to be submitted shortly.
Corcept is also studying relacorilant in combination with other drugs for treating different cancer indications.
The phase III ROSELLA study is evaluating relacorilant in combination with nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer, with data from the same expected by 2024 end. Another study is evaluating relacorilant in combination with pembrolizumab for treating patients with adrenal cancer along with cortisol excess.
CORT's Zacks Rank & Other Key Picks
Corcept currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the biotech sector are Immunocore Holdings plc (IMCR - Free Report) , Spero Therapeutics, Inc. (SPRO - Free Report) and Castle Biosciences, Inc. (CSTL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Immunocore’s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time. Year to date, shares of IMCR have declined 55%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 25.57%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Loss per share estimates for 2025 have narrowed from $1.54 to 79 cents during the same time. Year to date, shares of SPRO have declined 21.7%.
SPRO’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 94.42%.
In the past 60 days, estimates for Castle Biosciences’ 2024 bottom line have moved from a loss of 58 cents per share to earnings of 34 cents per share. Loss per share estimates for 2025 have narrowed from $2.13 to $1.84 during the same time. Year to date, shares of CSTL have surged 36.6%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.